The Technical Analyst
Novavax Inc [NVAX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Novavax Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
1.29% $3.94
America/New_York / 19 apr 2024 @ 11:21
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 551.43 mill |
| EPS: | -5.41 |
| P/E: | -0.730 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 139.95 mill |
| Avg Daily Volume: | 7.43 mill |
| RATING 2024-04-18 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.730 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.12x |
| Company: PE -0.730 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 3.60 - 4.28 ( +/- 8.71%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-01 | Trizzino John | Buy | 144 000 | Restricted Stock Units |
| 2024-03-01 | O'hara Elaine | Buy | 120 000 | Restricted Stock Units |
| 2024-03-01 | Kelly James Patrick | Buy | 176 000 | Restricted Stock Units |
| 2024-03-01 | Dubovsky Filip | Buy | 144 000 | Restricted Stock Units |
| 2024-03-01 | Casey Mark J | Buy | 12 000 | Restricted Stock Units |
| INSIDER POWER |
|---|
| 62.95 |
| Last 99 transactions |
| Buy: 1 952 927 | Sell: 481 828 |
Forecast:
13:01 - $3.97
Live Trading Signals (every 1 min)
Forecast
1: 11:31 - $3.94
Forecast 2: 12:21 - $3.96
Forecast 3: 13:01 - $3.97
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $3.94 (1.29% ) |
| Volume | 0.704 mill |
| Avg. Vol. | 7.43 mill |
| % of Avg. Vol | 9.47 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For NVAX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $3.79 | N/A | Active |
|---|
NVAX
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Latest Press Releases
2024-04-18 12:15:00 - Press Release
Levi & Korsinsky, Llp Notifies Shareholders Of Novavax, Inc. (nvax) An Upcoming Claims Deadline In A Class Action Settlement
New york, ny / accesswire / april 18, 2024 / levi & korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against novavax, inc. (nasdaq:nvax). the settlement provides for a fund of $47,000,000 to benefit class members.
2024-04-16 12:30:00 - Press Release
Levi & Korsinsky, Llp Notifies Shareholders Of Novavax, Inc. (nvax) An Upcoming Claims Deadline In A Class Action Settlement
New york, ny / accesswire / april 16, 2024 / levi & korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against novavax, inc. (nasdaq: nvax). the settlement provides for a fund of $47,000,000 to benefit class members.
2024-04-11 12:30:00 - Press Release
Levi & Korsinsky, Llp Notifies Shareholders Of Novavax, Inc. (nvax) An Upcoming Claims Deadline In A Class Action Settlement
New york, ny / accesswire / april 11, 2024 / levi & korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against novavax, inc. (nasdaq:nvax). the settlement provides for a fund of $47,000,000 to benefit class members.
2024-04-09 12:30:00 - Press Release
Levi & Korsinsky, Llp Notifies Shareholders Of Novavax, Inc. (nvax) An Upcoming Claims Deadline In A Class Action Settlement
New york, ny / accesswire / april 9, 2024 / levi & korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against novavax, inc. (nasdaq: nvax). the settlement provides for a fund of $47,000,000 to benefit class members.
2024-04-04 12:20:00 - Press Release
Levi & Korsinsky, Llp Notifies Shareholders Of Novavax, Inc. (nvax) An Upcoming Claims Deadline In A Class Action Settlement
New york, ny / accesswire / april 4, 2024 / levi & korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against novavax, inc. (nasdaq:nvax). the settlement provides for a fund of $47,000,000 to benefit class members.
Latest News
2024-04-15 06:43:22 - Reuters
Hedge fund Shah Capital recommends two new candidates for Novavax board
U.S.-based hedge fund Shah Capital on Monday recommended the appointment of two new independent directors to the Novavax board.
2024-04-15 06:39:00 - Market Watch
Novavax failed to capitalize on fears surrounding mRNA vaccines, activist investor says
Hedge fund Shah Capital on Monday called for an “urgent shake up” at the board of Novavax over claims its management has failed to capitalize on safety concerns surrounding mRNA vaccines to boost sales of its own non-mRNA COVID-19 vaccine.
2024-04-13 16:22:00 - The Motley Fool
Better Buy: Bluebird Bio Vs. Novavax
Bluebird Bio's most recently approved gene editing therapy looks highly promising. Novavax has generated decent revenue from its coronavirus vaccine.
2024-04-12 06:35:00 - The Motley Fool
Down 60% From Its 52-Week High, Is Novavax Stock a Buy?
Novavax's business still centers heavily around COVID-19. This year, it expects up to $1 billion in revenue.
2024-04-11 10:16:15 - Zacks Investment Research
Will Novavax's (NVAX) Strategic Reshaping Curb Cash Burn?
To extend its existing cash runway and curb cash burn, Novavax (NVAX) initiates multiple restructuring initiatives that are aimed at lowering operating expenses and enhancing profitability.
2024-04-09 07:01:31 - MarketBeat
The Top 5 Analysts Ranked by Marketbeat and Stocks They Cover
Marketbeat's many investor tools include analysts' rankings and sentiment trackers. These tools help investors and traders gauge market sentiment, showing trends and changes, updated revisions, and new reports.
2024-04-03 09:56:13 - Zacks Investment Research
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
2024-04-02 10:15:00 - The Motley Fool
1 Beaten-Down Stock to Buy and 1 to Avoid Like the Plague
Teladoc's position in the growing telemedicine industry could help it turn things around. Novavax's only approved product is going nowhere and its pipeline has too little to offer.
2024-03-15 09:15:32 - 24/7 Wall Street
This Biotech Stock Plunged 20% but Wall Street Expects a 195% Recovery
Investing in biopharmaceutical stocks comes with more risks than some other types of stocks.
2024-03-09 01:59:00 - The Motley Fool
1 Beaten-Down Stock That's Still Not Worth Buying
Novavax's coronavirus franchise isn't performing well. The company has no other product close to approval.